þ hematopoietic progenitors with a prominent proliferation of the megakaryocytic (MK) population are the hallmarks of the myeloproliferation in myelofibrosis with myeloid metaplasia (MMM). Analyzing the potential contribution of the stem cell leukemia (SCL) gene in MMM myeloproliferation was doubly interesting for SCL is expressed both in primitive-uncommitted progenitor cells and erythroid/MK cells, its transcription differentially initiating from promoter 1b and 1a, respectively. Our results show that: (i) the expression of SCL transcript is increased in peripheral blood mononuclear cells (PBMCs) from patients; (ii) SCL gene transcription is altered in MMM CD34
Introduction
Myelofibrosis with myeloid metaplasia (MMM), a chronic myeloproliferative disorder also named as idiopathic myelofibrosis or agnogenic myeloid metaplasia, is a clonal process with a multipotent stem cell origin. The main biological hallmarks of this rare disease are bone marrow fibrosis and myeloproliferation with extramedullary hematopoiesis.
1,2 Genetic and enzyme studies have demonstrated the clonal nature of the hematopoietic pluripotent stem cell expansion and the polyclonality of the neighboring proliferating fibroblasts, 3, 4 bone marrow fibrosis being considered as a reactive process resulting from the stimulation of nonclonal fibroblasts by megakaryocytic (MK)-derived growth factors. [5] [6] [7] The myeloproliferation observed in MMM is characterized by an increased number of circulating CD34 þ hematopoietic progenitors with a prominent proliferation of the MK population. 8, 9 While recent data have improved our current knowledge about cellular mechanisms that could participate in the clonal proliferation in MMM, 10 the underlying molecular genetic alteration(s) remains unknown as, although 30% of the patients may have cytogenetic abnormalities, MMM lacks a unique chromosomal rearrangement that marks the site of oncogene involved in the pathogenesis of the disease. 11 The molecular events that influence the emergence and expansion of hematopoietic stem cells mainly rely on regulatory nuclear factors. Such transcriptional regulators serve critical roles in hematopoietic cell proliferation and differentiation; some of these transcription factors are lineage restricted and are likely to play a pivotal role in the control of hematopoietic lineage commitment and further differentiation. 12 Among these lineage-restricted regulators critical to the proper development of hematopoietic cells, the stem cell leukemia (SCL) protooncogene (also known as tal-1 or tcl-5) encodes a protein belonging to the helix-loop-helix (HLH) family that is predominantly expressed in hematopoietic cells. 13 SCL was originally identified by virtue of a chromosomal rearrangement in T-cell acute lymphoblastic leukemia and is oncogenic when expressed in T lymphocytes. 14, 15 . From gene targeting experiments, SCL has emerged as an essential candidate regulator for early hematopoietic development. 16 Within the hematopoietic compartment, SCL is expressed in multipotent myeloid progenitors prior to lineage commitment and in erythroid, mast and MK cells, its expression being repressed after commitment to nonexpressing lineages. 17, 18 The SCL gene displays a complex pattern of transcription as multiple transcripts have been identified. Indeed, SCL transcription is driven by two promoters in alternate 5 0 exons, promoters 1a and 1b. 19, 20 Human and murine promoters are highly conserved and exhibit lineagerestricted activity. Transcriptional activity of promoter 1a has been demonstrated in erythroid, MK and masts cells. In contrast, promoter 1b is silent in erythroid and MK cells but active in CD34 þ primitive myeloid cells and in mast cells. 21, 22 A third SCL promoter, termed promoter IV, has been recently identified; 23 it does not by itself display cell type specificity. 24 The basic HLH (bHLH) protein encoded by the SCL gene exists as two major isoforms; a 42 kDa full-length protein and a 22 kDa amino-truncated form resulting from differential mRNA splicing, both are phosphorylated on serine and localize to the nucleus. 25 The clonal amplification of hematopoietic cells from a pluripotent stem cell, particularly of cells belonging to the MK compartment and the possible pathogenic contribution of these latter in the promotion of bone marrow fibrosis in MMM, 26 led us to seek for the possible involvement of a deregulated expression of SCL in such an amplification of the CD34 þ progenitor population and its commitment to the MK lineage. The data reported here, showing an altered expression and transcription of SCL in MMM patients mononuclear cells and purified CD34
þ progenitor cells, respectively, underline the potential contribution of such alterations of SCL, a lineage-restricted transcription factor crucial in hematopoiesis, to the pathogenesis of myeloproliferation in MMM.
Materials and methods

Patients
Myelofibrosis precluding successful bone marrow aspiration the study was performed in patients' cells isolated from peripheral blood. Samples were obtained from patients with MMM documented by standard clinical and hematological criteria (according to the Polycythamia Vera Study Group criteria); they were 49-75 years old and not receiving chemotherapy at the time of the study.
Normal blood samples were obtained from leukapheresis of healthy donors who were between 35 and 65 years old. Bone marrow samples were obtained from healthy individuals undergoing hip prosthesis surgery (mean age 68 þ 7 years).
All samples were obtained after informed consent.
Reagents
Sodium orthovanadate, phenylmethyl-sulfonylfluoride, dithiothreitol (DTT), protease inhibitors were obtained from Sigma.
The following directly conjugated monoclonal antibodies: phycoerythrin (PE)-anti-human CD34 (PE-HPCA2), and fluorescein isothiocyanate (FITC)-anti-CD41 were purchased from Coulter-Immunotech (Marseille, France) and used for CD34 þ cell isolation and cell sorting. Two polyclonal SCL/tal1-specific rabbit antisera were kindly provided by Professor R Baer (Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, USA). Antiserum1080 was obtained by immunizing with a GST-fusion protein containing the aminoterminal 121 residues of human SCL/tal1. Antiserum 370 was raised against a GST-fusion protein containing the carboxyterminal 94 residues. 27 These antisera were used for immunoblotting and gel shift experiments. The monoclonal antibody BTL73 raised against the full-length SCL/tal1 protein, a gift from Drs D Mason and K Pulford (University Department of Cellular Science, University of Oxford, John Radcliffe Hospital, Oxford, UK) was used for immunocytochemistry assays. 28 Chemiluminescence (ECL) reagents and Hyperfilms were from Amersham (Arlington Height, IL, USA).
Isolation of hematopoietic cells
All samples were collected on preservative-free heparin. Mononuclear cells were separated from peripheral blood from 20 MMM patients and 12 healthy subjects by centrifugation through Ficoll-Hypaque (d ¼ 1.077 g/ml; Pharmacia, Uppsala, Sweden) at 450 g for 30 min at room temperature. After washing with RPMI 1640 (Gibco), two gentle centrifugation steps (91 g for 7 min) were performed to remove platelets; the unfractionated low-density mononuclear cells were collected. Aliquots of mononuclear cells isolated from patients' and normal peripheral blood mononuclear cells (PBMC) were used for RNA extraction and cell lysate preparation. CD34 þ progenitor cells were isolated from PBMCs of 14 patients and from the bone marrow and the unmobilized blood from 14 and seven healthy donors, respectively, using the Milteny MiniMacs Immunomagnetic Separation system and the CD34 þ progenitor cell isolation kit. 29 The purity of cell preparations was assessed by flow cytometry analysis using a Coulter Elite flow cytometer (Beckman-Coulter). Whatever their origin CD34 þ cell preparations were X97% pure.
Cell sorting
In some experiments, CD34 þ subpopulations were sorted according to their CD41 expression. CD34 þ cells, purified either from MMM patients' blood or from bone marrow and unmobilized blood of healthy subjects (as described above) were labeled with PerCP anti-CD34 (8G12 clone, Becton Dickinson) and PE anti-CD41 (5B12 clone, Dako) antibodies. To eliminate a possible contamination by CD42 þ platelets or by CD34
þ cells on which CD42 þ platelets could have stuck, cells were also labeled with an FITC anti-CD42b antibody (SZ2 clone, Beckman Coulter) and were excluded from the cell sorting. CD34 þ cells isolated from the blood of six normal donors were pooled after purification to obtain a sufficient number of CD34 þ cells to perform cell sorting. After washing, purified CD34 þ cells were resuspended in RPMI 1640 and sorted into a CD34 þ CD42 À CD41 À and a CD34 þ CD42 À CD41 þ subpopulation using a Coulter Elite flow cytometer (Coulter Electronics, Margency, France).
Reverse transcriptase-polymerase chain reaction (i) RNA extraction: Total RNA was extracted from PBMC and CD34 þ cells lysed in guanidium isothiocyanate buffer according to Chomczynski and Sacchi. 30 (ii) Reverse transcriptase-polymerase chain reaction (RT-PCR) experiments: Single-stranded cDNA was synthetized as previously described from 1 mg whole RNA using M-MLV RT (Gibco-BRL, France) and random hexamers as primers (PdN6, Boehringer-Mannhein, France).
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Semiquantification of SCL/tal1 gene expression was performed after coamplification and normalization with an internal control b 2 -microglobulin sequence. The nucleotide sequence of the SCL upstream primer was: 5 0 -CAATCGAGTGAAGAGGA GACCTTC-3 0 (cDNA 1069-1092) and the downstream primer was: 5 0 -AGGACTTCATTCTTGCTGAGCTTC-3 0 (cDNA 1263-1240) yielding a 195 bp product. These primers amplify the bHLH domain sequences present in all SCL mRNA species detected so far. For b 2 -microglobulin, the upstream primer was: 5 0 -AAA GATGAGTATGCCTGCCG-3 0 (cDNA 320-339) and the downstream primer was: 5 0 -ACTCAATCCAAATGCGGC-3 0 (cDNA 439-428) yielding a 165 bp product.
PCR was performed with a thermocycler (MJ Research, Watertown, MA, USA); the PCR products were visualized on a 2% agarose gel by ethidium bromide staining, and analyzed on a 7% polyacrylamide gel. Semiquantification was determined by calculating the ratio of SCL to b 2 -microglobulin signals after ethidium bromide staining followed by analysis by densitometric scanning using a video camera (Imagert, Appligene, France), and further analysis using Image 144611 MacIntosh software. The results were represented as curves of cumulative frequencies; each value of the axis (x-axis) represents the cumulative percentage of individuals whose value of the ratio SCL/b 2 -microglobulin is less than or equal to the data point (y-axis). cDNA from human MK Dami cells was used as a positive control for PCR. Negative control was the product of reverse transcription where RNA was omitted.
Transcriptional activity of promoters 1a and 1b was analyzed by qualitative RT-PCR using two different couples of primers allowing the identification of transcripts initiated at 1a and 1b. These specific primers were: (i) for promoter 1a: 5 0 -CGCTCAGGACCGGGCCTCAA (forward exon 1a) and 5 0 -CTCCCGGCTGTTGGTGAA (backward exon 6), yielding a 200 bp product; (ii) for promoter 1b: 5 0 -TGTGCATGCGGTGG GATTGT (forward exon 1b) and 5 0 -GCGGAAGCCGAGGAA GAGGAT (backward exon 3) yielding a 220 bp product.
Electrophoretic mobility shift analysis
Nuclear extracts and whole-cell extracts were prepared as previously described 32 from PBMCs and CD34 þ progenitor cells, respectively, and used for electrophoretic mobility shift assays (EMSAs).
32 P-labeled DNA probe was prepared from oligonucleotides containing the SCL/tal1-binding consensus sequence (the core E-box sequence underlined): CTAGAACCT GAACAGATGGTCGGCTT (top strand). Double-stranded oligonucleotide of the indicated sequence was end labeled with Klenow DNA polymerase (Klenow Fill-in kit, Stratagene) and incubated with 20 mg of cell extracts, that in some cases were preincubated with 1 ml of SCL rabbit antiserum (no. 1080), in 30 ml of a binding buffer consisting of 50 mM HEPES, pH 7.9, 25 mM Tris/HCl, 5 mM DTT, 50% glycerol, 500 ml BSA and 5 mg of salmon sperm for 20 min at 41C. Protein-DNA complexes were resolved by electrophoresis on 5% polyacrylamide gels. Dried gels were exposed to film and analyzed by autoradiography.
Cellular localization of SCL protein
SCL / tal1 protein was localized in patients' PBMC smeared onto glass slides by cytospin centrifugation. Cells were permeabilized with PBS/Triton 0.1% for 15 min at room temperature; after washing the cells were incubated overnight at 41C with the monoclonal anti-SCl antibody BTL73. After being washed in PBS, the cells were subsequently incubated for 90 min at 41C in the dark with a 1:40 dilution of PE-labeled goat anti-mouse antibody (Caltag Laboratories, USA).
The colocalization of SCL and gpIIbIIIa (CD41) was assessed by dual staining procedure by subsequently incubating cells with a FITC-labeled anti-CD41 monoclonal antibody (CoulterImmunotech, France) for 2 h at 41C in the dark.
Mouse immunoglobulins IgG1 were used as negative controls.
Results
Expression and transcription of SCL in patients' PBMCs
We first determined whether the expression of SCL was altered in MMM patients and whether it would reflect the difference in cell type distribution in the PBMC compartment between patients and healthy subjects. For this set of semiquantitative RT-PCR experiments, we used a couple of primers that amplify the bHLH domain sequences present in all mRNAs detected so far. Analysis of data from 20 patients clearly indicated that SCL transcript levels were significantly higher in patients' PBMC than in PBMC from healthy individuals in which SCL was barely detectable (Po0.0001) ( Figure 1 ).
As promoters 1a and 1b have been shown specifically active in erythroid/MK cells and primitive progenitors, respectively, RT-PCR analysis was performed to determine at which promoter SCL transcription was initiated in the patients' PBMC population. RT-PCR experiments were conducted, for each sample, using two different couples of primers that result in the amplification of transcripts initiated at 1a and 1b, respectively.
As shown in Figure 2 , SCL transcript was highly detectable in most of the patients' PBMC samples analyzed using a couple of primers specific for transcript initiated at 1a. By contrast, SCL transcript was faintly detectable in the majority of the patients' samples analyzed using primers amplifying transcript initiated at promoter 1b.
Expression and transcription of SCL in CD34
þ cells purified from patients' blood
Based on the hypothesis of a clonal expansion from a multipotent progenitor cell in MMM, the high levels of SCL transcript detected in patients' PBMC prompted us to analyze its expression in MMM CD34 þ progenitor cells. Fibrosis precluding any successful bone marrow aspiration, CD34 þ cells were purified from patients' peripheral blood. Control samples SCL transcription initiated at promoter 1a and 1b in PBMCs. The transcriptional activity of both promoters was assessed by RT-PCR using two different couples of primers allowing the identification of transcripts initiated at 1a (200 bp) and 1b (220 bp). The human MK cell line Dami was used as a positive control.
SCL gene in
While displaying a bimodal pattern of expression, SCL transcript was highly expressed in the majority of the CD34 þ patients' cell samples (Figure 3) . Moreover, the overall results obtained from MMM CD34 þ cells indicated that SCL level was significantly higher in patients when compared with CD34 þ cells from NBM in which the variability of expression was greater (Po0.03). Besides, it appeared that the levels of SCL transcript were similarly high in normal blood CD34 þ cells and in the majority of patients' CD34 þ cells. As the primary human CD34 þ cell population represents a range of cell types from most primitive to committed progenitor cells, we took advantage of the specificity of activity of promoters 1a and 1b to examine more acutely the SCL transcription in the different populations of purified CD34 þ progenitor cells, that is, in CD34 þ cells from patients vs their normal counterparts.
As illustrated in Figure 4 , in CD34 þ cells purified from patients' blood (a), NBM (b) and normal blood (c), SCL transcript was observed in PCR experiments using couples of specific primers allowing the identification of transcripts initiated at 1a and 1b, thus showing that both promoters are used in these cell populations. However, in all three CD34 þ cell populations, the SCL transcript initiated at 1a was much more highly expressed than the 1b initiated transcript; particularly, this latter was hardly detectable in CD34 þ cells from normal blood (Figure 4c ).
SCL transcription initiated at promoter 1b in sorted
In all three CD34 þ cell populations, that is, from patients' blood, bone marrow and blood from healthy donors, SCL transcript was mainly initiated at promoter 1a, which suggested the presence of erythro/MK-committed progenitors in these populations. In a number of CD34 þ cell samples, SCL transcription appeared to be also driven from promoter 1b, thus suggesting the presence of more primitive progenitors in these cell samples.
The differences in levels of 1b initiated SCL transcription in CD34 þ cells from patients and NBM vs normal blood prompted us to better define these CD34 þ cell subset(s). Taking into account the prominent place of the MK lineage in MMM, CD34 þ cells purified from patients' blood, bone marrow and peripheral blood from healthy subjects were sorted according to their CD41 expression into CD34 þ CD41 þ and CD34 þ CD41 À subpopulations, as CD41, that is, gpIIbIIIa, is a marker of the MK lineage. The percentage of CD34 þ CD41 þ and CD34 þ CD41 À cells in the three aforementioned CD34 þ populations was assessed by flow cytometry analysis ( Table 1) .
The gating strategy of cell sorting and the yield of purification of the sorted subsets that was up to 99% are illustrated in Figure 5 . Transcription initiated at promoter 1b was then assessed in both CD34 þ CD41 þ /À subpopulations, as promoter 1b is assumed to be active in primitive multipotent progenitors.
In CD34 þ progenitor populations from peripheral blood and bone marrow from healthy individuals, 1b initiated SCL þ cells from healthy subject peripheral blood (') was performed as in Figure 1 and the results were expressed as curves of cumulative frequencies. Analysis of transcription initiated from promoter 1a and 1b in CD34 þ cells from patients' blood (a), bone marrow (b) and peripheral blood (c) from healthy subjects. SCL transcription initiated at both promoters was assessed as described for Figure 2 . As previously the human MK cell line Dami was used as a positive control. Table 1 Flow cytometry analysis of CD34 + cell populations
n ¼ number of samples. Results are shown as mean7s.d. CD34 + cell populations were purified from NBM, normal unmobilized peripheral blood (NPB) and blood from patients with MMM.
SCL gene in myelofibrosis with myeloid metaplasia V Steunou et al transcription was observed in the four samples corresponding to both CD34 þ CD41 þ and CD34 þ CD41 À subpopulations ( Figure 6 ). In contrast, in CD34 þ cells from patients' blood, SCL transcript was observed only in the CD34 þ CD41 À subpopulation. To ascertain whether these latter findings, that is, the lack of 1b initiated transcript in patients' CD34 þ CD41 þ cells were reliable, RT-PCR experiments were conducted using increasing amounts of cDNA from these sorted cells; such further assays resulted in similar results, thus confirming the lack of 1b initiated transcript in patients' CD34 þ CD41 þ progenitor cells.
SCL protein in patients' cells
We then determined whether the cells from patients who expressed the SCL transcript also produced the SCL protein.
Using the monoclonal antibody BTL73 raised against the fulllength SCL/tal1 protein allowed us to detect the SCL protein in patients' blood cells. Actually, a punctuate granular nuclear labeling was observed together with a cytoplasmic labeling within cells of the MK lineage, as shown by dual staining with an anti-gpIIbIIIa antibody (anti-CD41) ( Figure 7) . However, the overall SCL staining seemed to be cytoplasmic rather than nuclear, inasmuch as the intensity of nuclear staining varied from cell to cell with some cells in which nuclear labeling was discrete or undetectable.
Besides, in nuclear extracts and immunoprecipitates from patients' mononuclear cells and CD34 þ progenitor cells, Western analysis using antiserum 1080 generated to the SCL amino-terminal residues, allowed us to detect a protein of approximately 45 kDa (data not shown), the size of which is consistent with that of the full-length SCL protein.
DNA-binding potential of SCL in cells from patients
To evaluate the DNA-binding activity of endogenous SCL protein from patients' cells, mobility shift assays were carried out using a radiolabeled oligonucleotide probe containing the SCL/tal1 consensus E-box sequence. A SCL-containing protein-DNA complex was noted following incubation of patients' cell nuclear extracts (PBMC) (data not shown) or patients' whole-cell extracts (CD34 þ cells) with radiolabeled probe (filled arrowhead, Figure 8) ; this complex was not observed in the presence of an excess of unlabeled specific competitor; when the cell extracts were treated with anti-SCL serum (no. 1080) the SCLcontaining complex was partly supershifted (open arrowhead).
Discussion
Given the crucial role of the SCL gene in normal hematopoiesis, that is, the development of pluripotent hematopoietic stem cells and their commitment to multiple (erythroid, mast and MK) lineages, investigating for potential alteration in the expression and/or functionality of SCL in MMM was of particular interest, as MMM is characterized by clonal myeloproliferation. In this study, we show that the expression of SCL is altered in PBMC and that SCL transcription initiated from promoter 1b is deregulated in CD34 þ progenitors from patients. Based on the specific transcriptional activity of promoter 1a and 1b, our results showing that SCL is mainly transcribed from promoter 1a in patients' PBMC strongly suggested that the increased expression of SCL transcript in patients' PBMC is CD34+CD41-CD42b-CD34+CD41-CD42b-
Figure 5
Cell sorting strategy and purity of sorted fractions. Stained cells were sorted according to CD34 and CD41 expression by using a Coulter Elite flow cytometer. For cell sorting, immunomagnetic-purified CD34 þ cells were gated on a first R1 region by selecting lymphomononuclear cells and excluding dead cells (FSC/SSC dot plot). A second region R2 corresponding to CD34 þ cells was drawn on a second dot plot (CD34/SSC) gated on R1. Two gates correspond-
þ cells were defined (R3 and R4, respectively). The purity of the CD34 þ CD42 À CD41 À and CD34 þ CD42 À CD41 þ sorted fractions was greater than 99% as established by the postsort flow cytometry analysis.
SCL transcription initiating from promoter 1b in patients' sorted CD34 þ CD41 À/ þ subpopulations. RT-PCR experiments using primers allowing the identification of the SCL transcript initiated at 1b were performed on CD34 þ cells purified from patients' blood (MMM), blood (NPB) and bone marrow (NBM) from healthy individuals, and sorted after dual labeling with anti-CD34 and anti-CD41 antibodies into CD34
þ CD41 þ and CD34 þ CD41 À subpopulations using a Coulter Elite flow cytometer. Dami cells were used as a positive control (CT).
SCL gene in myelofibrosis with myeloid metaplasia V Steunou et al related to the presence of circulating MK cells, including MKcommitted progenitors, MK precursors and mature cells, in patients' blood. 26 Dual immunostaining with anti-SCL and antigpIIbIIIa monoclonal antibodies confirmed this hypothesis. However, in some patients presenting erythromyelemia, circulating erythroblasts might also participate in such an increase. More primitive pluripotent progenitors in sufficient amount probably accounted for promoter 1b initiated SCL transcript detected in PBMC from patients while, due to their extremely low number in normal blood, it was undetectable in PBMC from healthy donors, before CD34 þ cell purification (data not shown). Thus, these results likely reflect the constitution of the patients' blood cell compartment featured by a highly increased number of circulating primitive and committed CD34 þ progenitor cells, with a prominent amplification of the MK population. 1 
Concerning the CD34
þ progenitors, the overall expression of SCL transcript was significantly increased in patients CD34 þ cells when compared to bone marrow CD34 þ cells from healthy individuals (Po0.03), but similarly high than in normal blood CD34 þ cells. Although no difference was observed in the expression levels of SCL between CD34 þ cells from MMM and normal blood, analysis of the 1b SCL transcription suggested that the distribution of CD34 þ cells was somewhat different in patients' and normal blood primary CD34 þ cells ranging from most primitive to committed progenitors. Actually, while the levels of SCL transcript initiating from 1b were similar in CD34 þ cells from NBM and patients' blood, SCL transcript initiating at 1b was more hardly detectable in the CD34 þ population from normal blood, which might be related to a lesser percentage of primitive-uncommited cells in normal blood. This contention is supported by the finding that no 1b initiated transcript was detectable in PBMC from normal blood before CD34 þ cell purification (data not shown). In contrast, 1a initiated SCL transcript was highly detectable in all three CD34 þ populations, which suggested that the extent of the erythro/MK-committed Immunodetection of the SCL protein in patients' PBMCs. The localization of SCL was determined using the monoclonal antibody BTL73 raised against the full-length SCL protein and subsequent labeling with a PE-labeled goat anti-mouse antibody (A). The identity of the expressing cells was defined using a FITC-labeled anti-CD41 monoclonal antibody (B). A punctate nuclear and a cytoplasmic staining of SCL is seen in CD41 positive cells. Under the same experimental conditions negative controls for SCL (C) and CD41 (D) do not show any immunopositivity. Hoechst staining allowed the visualization of cell structures (E).
SCL gene in myelofibrosis with myeloid metaplasia V Steunou et al progenitor population is significant in these different CD34 þ cell populations. When analyzing SCL transcription initiated at 1b in sorted CD34 þ CD41 þ /À subsets, SCL transcript was detectable in both CD41 þ and CD41 À subpopulations from NBM and normal blood while, in patients' progenitors, 1b SCL transcription was observed only in the CD34 þ CD42 À CD41 À subpopulation. The finding of 1b initiated SCL transcription in the CD34 þ CD42 À CD41 þ subpopulation could appear paradoxal as promoter 1b has been shown to be active in primitive multipotent progenitors, 22 whereas CD41, that is, the GPIIb-IIIa integrin is known to be a marker expressed throughout the differentiation of the MK lineage. However, evidence that both murine and human GPIIb promoters are transcriptionally active in multipotent primitive cells, 33 and that GPIIb-IIIa is also expressed in early multilineage progenitor cells has been recently provided. [34] [35] [36] Such multipotent CD34CD41-expressing progenitors still containing myeloerythroid potential 37 could likely account for the SCL transcription initiating from promoter 1b in the CD34 þ CD41 þ subset sorted from bone marrow and blood from normal donors.
Remarkably, in MMM patients, 1b initiated transcript was detected only in the CD34 þ CD41 À subpopulation that likely corresponded to more primitive progenitors. Distant positive or negative regulatory elements, 38 chromatin structure surrounding 39 and methylation status 20, 22 have been shown to be crucial for full transcriptional activity of SCL promoters. Particularly, methylation silencing of gene promoters has been found to play a part in the etiology of human neoplasia. 40 It has been demonstrated that the endogenous SCL promoter was predominantly unmethylated in primitive myeloid cell lines, which fully accorded with the transcriptional activity of the SCL promoter region. 22 Thus, the transcriptional inactivity, that is, the apparent 'shut-off' of the SCL 1b initiated transcription observed in a subset of pathological CD34 þ CD41 þ progenitors, could result from alteration in the methylation status of promoter 1b in this cell subset. Alternatively, the specific absence of promoter1b-driven SCL transcription in CD34 þ CD41 þ patient samples could suggest a numerically preponderant compartment of more mature MK-lineage cells in patients vs controls, thus emphasizing the anomalies along the MK pathway in MMM.
The SCL protein was detected in hematopoietic cells from patients by Western analysis (data not shown) and by immunocytostaining. Interestingly, the anti-SCL monoclonal antibody that we used labeled the nuclei and the cytoplasm of patients' circulating MK cells, which is in contrast with the sole SCL nuclear staining previously reported in megakaryocytes from adult NBM. 41 Constructs lacking the basic domain of the SCL gene have demonstrated protein in the cytoplasm. 42 The nuclear immunolocalization of SCL protein in patients' cells and the SCL-containing protein-DNA complex that we detected by EMSA are in keeping with the presence of a bHLH region, DNA binding within the protein expressed in patients. Alternatively, it is known that cell cycle and phosphorylation can affect the subcellular localization of transcription factors. Particularly, during phosphorylation the protein may be located in the cytoplasm. 43 As SCL protein undergoes phosphorylation at serine residues, it is likely that both nuclear and cytoplasmic staining may reflect the genuine localization of SCL in patients' cells, possibly resulting from alteration of the SCL phosphorylation state in MMM patients.
The results from band shift assays demonstrated that the DNAbinding ability of the SCL protein present in patients' cells is unaffected. SCL /tal1 polypeptides are unable to form bHLH homodimers but interact with other HLH transcription factors to heterodimerize and bind to DNA. 25 This, together with possible changes in the accessibility of the SCL-containing complex in primary cells due to conformational alteration, could account for the incomplete abrogation of the SCL-containing protein-DNA complex that we observed after preincubation of cell extracts with SCL antiserum.
Our findings showing alterations in the expression and transcription of SCL in MMM patients' hematopoietic cells shed novel insight into the pathogenesis of MMM. Such a new insight is strengthened by data showing that the overexpression of SCL in human primitive CD34 þ progenitors enhanced MK differentiation, 44, 45 and that, although little is yet known about the identity of its target genes, SCL is required for the expression and function of c-kit, the receptor for the early acting cytokine stem cell factor. 46 Interestingly, elevated expression and point mutation of c-kit in circulating progenitors have been reported in myeloproliferative disorders including MMM. 47, 48 Besides, it has been recently suggested that CD41 may be a direct target of SCL function. 49 Finally, with regards to the pathophysiology of a disease on which very little is still known, the relevance of our findings is stressed by recent data suggesting that transcription factor GATA-1 and cofactor FOG-1 that associate with SCL in a functional mutiprotein complex, could be involved in the development of MMM. 50, 51 Further work will now be required to elucidate the mechanism(s) participating in the disrupted transcription of SCL, a master regulator of primitive hematopoiesis, in a subset of MMM CD34 þ progenitors reported here.
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